This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology, Sanofi-Aventis Recherche & Développement. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,488 
1 out of 41 
1 out of 4 Years Active: 2022-2026
Title: Janet Van Adelsberg: Innovator in Rheumatoid Arthritis Treatment
Introduction
Janet Van Adelsberg is a notable inventor based in the United States, recognized for her contributions to the field of medical treatments, particularly for rheumatoid arthritis. Her innovative work focuses on developing compositions that utilize antibodies to target specific receptors in the human body.
Latest Patents
Janet holds a patent titled "Compositions For The Treatment Of Rheumatoid Arthritis And Methods Of Using Same." This invention provides compositions and methods aimed at treating and improving the symptoms of rheumatoid arthritis through the use of an antibody that specifically binds to the human interleukin-6 receptor (hlL-6R). Despite her significant contributions, she currently has 2 patents to her name.
Career Highlights
Throughout her career, Janet has worked with prominent companies in the biotechnology sector. She has been associated with Regeneron Pharmaceuticals, Inc. and Sanofi Biotechnology, where she has contributed her expertise in developing innovative treatments.
Collaborations
Janet has collaborated with esteemed colleagues, including Xiaohong Huang and Martine Jasson, who have supported her research and development efforts in the field of rheumatoid arthritis treatment.
Conclusion
Janet Van Adelsberg's work represents a significant advancement in the treatment of rheumatoid arthritis, showcasing her dedication to improving patient outcomes through innovative medical solutions. Her contributions to the field highlight the importance of research and collaboration in developing effective therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile